University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor

Maxwell V. Meng, M.D.

Urologic cancer surgeon

Dr. Maxwell Meng is a surgeon specializing in urologic cancers and laparoscopy. His clinical interests include the diagnosis and management of genitourinary malignancy and minimally invasive treatment of benign and malignant diseases. Meng, actively involved in developing new treatment technologies, is also experienced in robotic surgery.

Meng earned a medical degree at Johns Hopkins School of Medicine and completed general surgery and urology training at UCSF, where he also completed fellowships in urologic oncology and minimally invasive surgery. He is an associate professor in the UCSF Department of Urology.

Clinics

Prostate Cancer Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Prostate Cancer Risk and Prevention Clinic
1600 Divisadero St, Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Maxwell V. Meng

Education

John Hopkins University 1995

Residencies

UCSF Urology Dept., Urology 2001

Fellowships

UCSF Urology Dept., Urology 2002

Selected Research and Publications

  1. Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M. The role of active surveillance in the management of prostate cancer. J Natl Compr Canc Netw. 2013 Feb 1; 11(2):183-7.
  2. Meng MV. Commentary on "Laparoendoscopic single-site (LESS) partial nephrectomy short-term outcomes." Rais-Bahrami S, George AK, Montag S, Okhunov Z, Richstone L, The Arthur Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY: BJU Int 2012 (Epub ahead of print). Urol Oncol. 2013 Jan; 31(1):131-2.
  3. Meng MV. Commentary on "Radiofrequency ablation of incidental benign small renal mass: Outcomes and follow-up protocol." Tan YK, Best SL, Olweny E, Park S, Trimmer C, Cadeddu JA, Department of Urology, University of Texas Southwestern Medical School, Dallas, Texas, TX. Urol Oncol. 2013 Jan; 31(1):132-3.
  4. Meng MV. Commentary on "Predicting the histology of small renal masses using preoperative dynamic contrast-enhanced magnetic resonance imaging." Kim JH, BaeJH, Lee KW, Kim ME, Park SJ, Park JY, Department of Urology, Soonchunhyang University Hospital, Seoul, Korea. Urol Oncol. 2013 Jan; 31(1):133-4.
  5. Meng MV. Commentary on "Benzodiazepine use possibly increases cancer risk: A population-based retrospective cohort study in Taiwan." Kao CH, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, Liang JA, Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan.: J Clin Psychiatry 2012;73(4):e555-e60. Urol Oncol. 2013 Jan; 31(1):130-1.
  6. Dang TT, Ziv E, Weinstein S, Meng MV, Wang Z, Coakley FV. Computed tomography and magnetic resonance imaging of adult renal cell carcinoma associated with xp11.2 translocation. J Comput Assist Tomogr. 2012 Nov; 36(6):669-74.
  7. Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM. A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer. J Urol. 2012 Dec; 188(6):2391-7.
  8. Meng MV. Editorial comment. Urology. 2012 Aug; 80(2):359; author reply 359-60.
  9. Meng MV, Nelson H. What's new in renal cell carcinoma. Bull Am Coll Surg. 2012 Aug; 97(8):65-6.
  10. Whitson JM, Harris CR, Meng MV. Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses. BJU Int. 2012 Nov; 110(10):1438-43.
  11. Harris CR, Whitson JM, Meng MV. Under-grading of <4 cm renal masses on renal biopsy. BJU Int. 2012 Sep; 110(6):794-7.
  12. Yang G, Villalta JD, Meng MV, Whitson JM. Evolving practice patterns for the management of small renal masses in the USA. BJU Int. 2012 Oct; 110(8):1156-61.
  13. Meng MV. Editorial comment. Urology. 2012 Jan; 79(1):31.
  14. Glass AS, Cooperberg MR, Meng MV, Carroll PR. Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr. 2012; 2012(45):202-6.
  15. Whitson JM, Reese AC, Meng MV. Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus. Urol Oncol. 2013 Feb; 31(2):259-63.
  16. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800.
  17. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011 Apr; 107(8):1232-7.
  18. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60.
  19. Whitson JM, Harris CR, Reese AC, Meng MV. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol. 2011 May; 185(5):1615-20.
  20. Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV. Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. Int Braz J Urol. 2011 Jan-Feb; 37(1):35-40;discussion 40-1.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.